Wed Dec 26, 2012, 08:55 PM
2on2u (1,843 posts)
Published in the journal Opthamology, Secondary Outcomes in a Clinical Trial of Carotenoids
with Coantioxidants versus Placebo in Early Age-Related Macular Degeneration.
Ophthalmology. 2012 Dec 5. pii: S0161-6420(12)00850-0. doi: 10.1016/j.ophtha.2012.08.040.
Secondary Outcomes in a Clinical Trial of Carotenoids with Coantioxidants versus Placebo in Early Age-Related Macular Degeneration.
Beatty S, Chakravarthy U, Nolan JM, Muldrew KA, Woodside JV, Denny F, Stevenson MR.
Macular Pigment Research Group, Waterford Institute of Technology, Waterford City, Waterford, Republic of Ireland.
To report the secondary outcomes in the Carotenoids with Coantioxidants in Age-Related Maculopathy trial.
Randomized double-masked placebo-controlled clinical trial (registered as ISRCTN 94557601).
Participants included 433 adults 55 years of age or older with early age-related macular degeneration (AMD) in 1 eye and late-stage disease in the fellow eye (group 1) or early AMD in both eyes (group 2).
An oral preparation containing lutein (L), zeaxanthin (Z), vitamin C, vitamin E, copper, and zinc or placebo. Best-corrected visual acuity (BCVA), contrast sensitivity (CS), Raman spectroscopy, stereoscopic colour fundus photography, and serum sampling were performed every 6 months with a minimum follow-up time of 12 months.
MAIN OUTCOME MEASURES:
Secondary outcomes included differences in BCVA (at 24 and 36 months), CS, Raman counts, serum antioxidant levels, and progression along the AMD severity scale (at 12, 24, and 36 months).
The differential between active and placebo groups increased steadily, with average BCVA in the former being approximately 4.8 letters better than the latter for those who had 36 months of follow-up, and this difference was statistically significant (P = 0.04). In the longitudinal analysis, for a 1-log-unit increase in serum L, visual acuity was better by 1.4 letters (95% confidence interval, 0.3-2.5; P = 0.01), and a slower progression along a morphologic severity scale (P = 0.014) was observed.
Functional and morphologic benefits were observed in key secondary outcomes after supplementation with L, Z, and coantioxidants in persons with early AMD.
The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Copyright © 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
The purpose of this post is to discuss health and health related issues. There is no advertising or selling of specific health products herein. No services or treatments are recommended or advised.
For information on medical advice on specific health concerns please see your healthcare provider.... he or she may or may not be familiar with the above information but that is just the way it is.
2 replies, 1483 views
Always highlight: 10 newest replies | Replies posted after I mark a forum
Replies to this discussion thread
Published in the journal Opthamology, Secondary Outcomes in a Clinical Trial of Carotenoids (Original post)
Response to 2on2u (Original post)
Wed Dec 26, 2012, 10:33 PM
TheBlackAdder (3,865 posts)
2. My 14-year-old daughter has pale optic nerves... she takes a multi and ocular supplements.
The ocular supplements consist of:
Vitamins A, C, D, E, Riboflavin, Zinc, Selenium, Chromium.
Active components: Bioflavinoids Complex, NAC, Taurine, Quercetin Dihydrate, Rutin, Lutein, Bilberry, L-Glutathione & Zeaxanthin.
This is great news to hear of such gains with them.